Hideharu Kimura1, Tatsuo Ohira2, Osamu Uchida3, Jun Matsubayashi4, Shinichiro Shimizu5, Toshitaka Nagao4, Norihiko Ikeda2, Kazuto Nishio6. 1. Department of Genome Biology, Kinki University Faculty of Medicine, 337-2 Ohno-Higashi, Osaka-Sayama, Osaka 589-8511 Japan. 2. Department of Surgery, Tokyo Medical University, 6-7-1 Nishi-shinjuku, Shinjuku-ku, Tokyo 160-0023, Japan. 3. Department of Respiratory Surgery, Funabashi Municipal Medical Center, 1-21-1 Kanasugi, Funabashi, Chiba 273-8588, Japan. 4. Department of Anatomic Pathology, Tokyo Medical University, 6-7-1 Nishi-shinjuku, Shinjuku-ku, Tokyo 160-0023, Japan. 5. Department of Pathology, Funabashi Municipal Medical Center, 1-21-1 Kanasugi, Funabashi, Chiba 273-8588, Japan. 6. Department of Genome Biology, Kinki University Faculty of Medicine, 337-2 Ohno-Higashi, Osaka-Sayama, Osaka 589-8511 Japan. Electronic address: knishio@med.kindai.ac.jp.
Abstract
INTRODUCTION: Clinical outcomes in non-small-cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutations have been reported to be correlated with the use of EGFR-tyrosine kinase inhibitors (EGFR-TKIs). Therefore, it is essential to confirm the presence of EGFR mutations using highly sensitive testing methods. In this study, we compared the performance of the cobas(®) EGFR Mutation Test (cobas EGFR assay) and the therascreen(®) EGFR RGQ PCR Kit (therascreen EGFR assay) for use as an in vitro diagnostic (IVD) product. METHODS: We extracted DNA from 150 formalin-fixed, paraffin-embedded tissue samples from 150 patients diagnosed with NSCLC, and performed a comparative study of the cobas EGFR and therascreen EGFR assay methods. All discordant results were re-analyzed by direct sequencing. RESULTS: The concordance rate between the cobas EGFR assay and the therascreen EGFR assay was 98.0% (145/148). EGFR mutations were detected at a frequency of 40.9% (61/149) in NSCLC specimens using the cobas EGFR assay and 40.2% (60/149) using the therascreen EGFR assay. Three discrepant results were found in this study. Two double mutations were detected by the cobas EGFR assay but only one in the therascreen EGFR assay. No invalid results resulted from sample analysis by the cobas EGFR assay. CONCLUSIONS: Our results show a high concordance rate (98.0%) of cobas EGFR assay with an existing IVD product, the therascreen EGFR assay. Since they are IVD diagnostic products, both assays proved to be simple, validated methods in detecting the most common, clinically significant EGFR mutations and proved to be helpful for appropriate treatment guidance for NSCLC patients.
INTRODUCTION: Clinical outcomes in non-small-cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutations have been reported to be correlated with the use of EGFR-tyrosine kinase inhibitors (EGFR-TKIs). Therefore, it is essential to confirm the presence of EGFR mutations using highly sensitive testing methods. In this study, we compared the performance of the cobas(®) EGFR Mutation Test (cobas EGFR assay) and the therascreen(®) EGFR RGQ PCR Kit (therascreen EGFR assay) for use as an in vitro diagnostic (IVD) product. METHODS: We extracted DNA from 150 formalin-fixed, paraffin-embedded tissue samples from 150 patients diagnosed with NSCLC, and performed a comparative study of the cobas EGFR and therascreen EGFR assay methods. All discordant results were re-analyzed by direct sequencing. RESULTS: The concordance rate between the cobas EGFR assay and the therascreen EGFR assay was 98.0% (145/148). EGFR mutations were detected at a frequency of 40.9% (61/149) in NSCLC specimens using the cobas EGFR assay and 40.2% (60/149) using the therascreen EGFR assay. Three discrepant results were found in this study. Two double mutations were detected by the cobas EGFR assay but only one in the therascreen EGFR assay. No invalid results resulted from sample analysis by the cobas EGFR assay. CONCLUSIONS: Our results show a high concordance rate (98.0%) of cobas EGFR assay with an existing IVD product, the therascreen EGFR assay. Since they are IVD diagnostic products, both assays proved to be simple, validated methods in detecting the most common, clinically significant EGFR mutations and proved to be helpful for appropriate treatment guidance for NSCLCpatients.
Authors: Deborah A Belchis; Li-Hui Tseng; Thomas Gniadek; Lisa Haley; Parvez Lokhandwala; Peter Illei; Christopher D Gocke; Patrick Forde; Julie Brahmer; Frederic B Askin; James R Eshleman; Ming-Tseh Lin Journal: Oncotarget Date: 2016-07-19
Authors: Peter B Illei; Deborah Belchis; Li-Hui Tseng; Doreen Nguyen; Federico De Marchi; Lisa Haley; Stacy Riel; Katie Beierl; Gang Zheng; Julie R Brahmer; Frederic B Askin; Christopher D Gocke; James R Eshleman; Patrick M Forde; Ming-Tseh Lin Journal: Oncotarget Date: 2017-05-20